拜耳集团Bayer AG (BAYZF) 2015年年度报告「OTC」.pdf

《拜耳集团Bayer AG (BAYZF) 2015年年度报告「OTC」.pdf》由会员分享，可在线阅读，更多相关《拜耳集团Bayer AG (BAYZF) 2015年年度报告「OTC」.pdf（361页珍藏版）》请在三个皮匠报告上搜索。

1、Annual ReportAugmented Version2015?CAGR22011-2015?CAGR22011-2015?CAGR22011-2015?CAGR22011-2015?CAGR22011-2015?CAGR22011-2015Cover picture/Bayer is focusing exclusively on its Life Science businesses.Our cover picture shows scientists Dr.Wen Chang from Crop Science and Dr.Daniel Forler(right)from Pha

2、rmaceuticals with a projected image of DNA.You can read more about Life Sciences in the Magazine section of this Annual Report beginning on page 10.Five-Year Summary:Bayer on Track for Success Five-Year Summary 2011 2012 2013 2014 2015 Change from 2014(%)million million million million million Bayer

3、 Group Sales 36,528 39,741 40,157 41,339 46,324+12.1 EBIT 1 4,149 3,928 4,934 5,395 6,250+15.8 EBIT before special items 2 5,025 5,639 5,773 5,833 7,069+21.2 EBITDA3 6,918 6,916 7,830 8,315 9,583+15.2 EBITDA before special items 4 7,613 8,280 8,401 8,685 10,266+18.2 EBITDA margin before special item

4、s 5 20.8%20.8%20.9%21.0%22.2%Income before income taxes 3,363 3,176 4,207 4,414 5,245+18.8 Net income 2,470 2,403 3,189 3,426 4,110+20.0 Earnings per share()from continuing and discontinued operations 6 2.99 2.91 3.86 4.14 4.97+20.0 Core earnings per share()from continuing operations 7 4.83 5.30 5.6

5、1 5.89 6.83+16.0 Gross cash flow 8 5,172 4,556 5,832 6,707 6,999+4.4 Net cash flow from continuing and discontinued operations 9 5,060 4,530 5,171 5,810 6,890+18.6 Net financial debt 7,013 7,022 6,731 19,612 17,449 11.0 Capital expenditures as per segment table 1,666 2,012 2,155 2,484 2,556+2.9 Rese

6、arch and development expenses 2,932 3,013 3,406 3,537 4,281+21.0 Return on equity 13.0%13.0%16.2%16.8%17.9%Equity ratio 36.5%36.1%40.5%28.8%34.4%Bayer AG million million million million million Net income 1,125 889 2,498 2,454 1,361 44.5 Allocation to(withdrawal from)retained earnings(239)(682)761 5